Enorama Pharma Gross Profit vs. Total Debt
| ERMA Stock | SEK 3.10 0.16 4.91% |
For Enorama Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Enorama Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Enorama Pharma AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Enorama Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Enorama Pharma AB over time as well as its relative position and ranking within its peers.
Enorama |
Enorama Pharma AB Total Debt vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Enorama Pharma's current stock value. Our valuation model uses many indicators to compare Enorama Pharma value to that of its competitors to determine the firm's financial worth. Enorama Pharma AB is one of the top stocks in gross profit category among its peers. It also is rated as one of the top companies in total debt category among its peers making up about 0.44 of Total Debt per Gross Profit. The ratio of Gross Profit to Total Debt for Enorama Pharma AB is roughly 2.29 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Enorama Pharma's earnings, one of the primary drivers of an investment's value.Enorama Total Debt vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Enorama Pharma |
| = | 3.9 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Enorama Pharma |
| = | 1.7 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Enorama Total Debt vs Competition
Enorama Pharma AB is rated as one of the top companies in total debt category among its peers. Total debt of Drug Manufacturers - Specialty & Generic industry is currently estimated at about 1.4 Billion. Enorama Pharma adds roughly 1.7 Million in total debt claiming only tiny portion of equities under Drug Manufacturers - Specialty & Generic industry.
Enorama Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Enorama Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Enorama Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Enorama Pharma's change in net profit over the period of time. It can combine multiple indicators of Enorama Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. Enorama Pharma AB is a subsidiary of Swede Unipharma AB. Enorama Pharma is traded on Stockholm Stock Exchange in Sweden.
Enorama Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Enorama Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Enorama Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Enorama Pharma's important profitability drivers and their relationship over time.
Use Enorama Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enorama Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enorama Pharma will appreciate offsetting losses from the drop in the long position's value.Enorama Pharma Pair Trading
Enorama Pharma AB Pair Trading Analysis
The ability to find closely correlated positions to Enorama Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enorama Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enorama Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enorama Pharma AB to buy it.
The correlation of Enorama Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enorama Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enorama Pharma AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enorama Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Enorama Pharma position
In addition to having Enorama Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SRI Sustainable Growth Thematic Idea Now
SRI Sustainable Growth
Socially responsible investments that include companies making a positive, sustainable or social impact and exclude those making a negative impact. The SRI Sustainable Growth theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SRI Sustainable Growth Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.